Isogenica

VHHs lack a light chain, so all antigen binding sits in one small domain that links easily to other VHHs. Build bispecifics, multispecifics, and mixed modality molecules from modular parts.

More than 100 programmes delivered, with multiple leads progressed to the clinic. At around 15 kDa, roughly 10% of the size of a conventional antibody, VHHs offer improved tissue and tumour penetration and can slot into ADC, T cell engager and CAR formats.

Raising on the back of proof-of-concept data? We deliver fee-for-service PoC work with no equity or royalty strings on rapid timlines. "We've genuinely valued their partnership." Thibault Harmand, PhD, Cerberus Therapeutics

The payload is only as good if it arrives at the destination. Meet our scientists at booth 423 to talk about VHHs as the targeting module for your conjugate, cell therapy or radioligand programme.

Selective depletion, receptor degradation and tissue-restricted targeting all need high-specificity binders. Talk to us about VHH discovery for immunology programmes.

Dual-targeting ADCs, degrader conjugates and novel payloads all ask more of the binder. A small, single-domain VHH gives you a defined conjugation site and room to build the format around it.